Loading
This system is how the result of testing fluid drained from around the lungs, heart or abdomen is reported, in six categories from non-diagnostic to cancer that started there or spread there.
The International System for Reporting Serous Fluid Cytopathology (Crothers and colleagues, 2020) has six diagnostic categories adapted from earlier cytopathology systems: non-diagnostic, negative for malignancy, atypia of undetermined significance, suspicious for malignancy, malignant primary (a cancer arising in the lining, such as mesothelioma) and malignant secondary (a cancer that has spread there). Each carries a risk of malignancy supported by meta-analysis.
Central tumours arise in the large airways, peripheral ones in the alveoli; both drain to hilar then mediastinal nodes, and the pleural lining is a separate cancer site.
Same organ: Mediastinal germ cell tumour, Pleuropulmonary blastoma (types I, Ir, II and III), Type A and type AB thymoma, Type B1 and type B2 thymoma, Type B3 thymoma, Micronodular thymoma with lymphoid stroma, Adenocarcinoma of the lung, Squamous cell carcinoma of the lung, Large cell carcinoma of the lung, Sarcomatoid carcinoma of the lung, Adenosquamous carcinoma of the lung, Invasive mucinous adenocarcinoma of the lung, Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung, Basaloid squamous cell carcinoma of the lung, Lymphoepithelial carcinoma of the lung, Pulmonary blastoma (adult), Non-small-cell lung cancer, Lung cancer (all types), Small-cell lung cancer, Pleural mesothelioma, Thymoma and thymic carcinoma, Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours), Inflammatory myofibroblastic tumour (IMT), EGFR-mutated non-small-cell lung cancer, ALK-positive non-small-cell lung cancer, KRAS G12C-mutant non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer, RET fusion-positive non-small-cell lung cancer, BRAF V600E-mutant non-small-cell lung cancer, HER2-mutant non-small-cell lung cancer, NTRK fusion-positive non-small-cell lung cancer, PD-L1-high non-small-cell lung cancer without a driver mutation, Resectable stage I to III non-small-cell lung cancer, Unresectable stage III non-small-cell lung cancer, Limited-stage small-cell lung cancer, Extensive-stage small-cell lung cancer, Lung neuroendocrine tumours (typical and atypical carcinoid), Large cell neuroendocrine carcinoma of the lung, Thymoma (WHO types A, AB, B1, B2 and B3), Thymic carcinoma
Showing the organ this term concerns: Mesothelioma.
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares Malignant pleural effusion, Malignant pleural effusion and ascites, Mesothelioma.
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares Malignant pleural effusion, Malignant pleural effusion and ascites.
Shares Malignant pleural effusion, Malignant pleural effusion and ascites, Mesothelioma.
Shares Malignant pleural effusion, Malignant pleural effusion and ascites, Mesothelioma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/